Imaging Patients with Kidney Disease—Weighing the Risks and Benefits
21. Morcos SK, Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?, Eur Radiol, 2011;21:496–500.
22. Chrysochou C, Power A, Shurrab AE, et al., Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium- enhanced magnetic resonance imaging, Clin J Am Soc Nephrol, 2010;5:484–9.
23. Prince MR, Zhang HL, Roditi GH, et al., Risk factors for NSF: a literature review, J Magn Reson Imaging, 2009;30:1298–308.
24. Perazella MA, Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm, Curr Opin Nephrol Hypertens, 2009;18:519–25.
25. Wang Y, Alkasab TK, Narin O, et al., Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines, Radiology, 2011;260:105–11.
26. Mayr M, Burkhalter F, Bongartz G, Nephrogenic systemic fibrosis: clinical spectrum of disease, J Magn Reson Imaging, 2009;30:1289–97.
27. Elmholdt TR, Jørgensen B, Ramsing M, et al., Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compund gadobutrol, NDT Plus 2010;3:285–7.
28. Wollanka H, Weidenmaier W, Giersig C, NSF after Gadovist exposure: a case report and hypothesis of NSF development, Nephrol Dial Transplant, 2009;24:3882–4.
29. Collidge T, Thomson P, Mark P, et al., Is this really a true case of NSF following Gadovist exposure alone?, Nephrol Dial Transplant, 2010;25:1352–3; author reply 3–4.
30. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN, Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure, Nephrol Dial Transplant, 2007;22:3179–85.
31. Broome DR, Girguis MS, Baron PW, et al., Gadodiamide- associated nephrogenic systemic fibrosis: why radiologists should be concerned, AJR Am J Roentgenol, 2007;188:586–92.
32. Marckmann P, Skov L, Rossen K, et al., Case–control study of gadodiamide-related nephrogenic systemic fibrosis, Nephrol Dial Transplant, 2007;22:3174–8.
33. Perazella MA, Reilly RF, Imaging patients with kidney disease: how do we approach contrast-related toxicity?, Am J Med Sci, 2011;341:215–21.
34. Van Praet JT, De Vriese AS, Prevention of contrast-induced nephropathy: a critical review, Curr Opin Nephrol Hypertens, 2007;16:336–47.
35. Persson PB, Hansell P, Liss P, Pathophysiology of contrast medium-induced nephropathy, Kidney Int, 2005;68:14–22.
36. Gleeson TG, Bulugahapitiya S, Contrast-induced nephropathy, AJR Am J Roentgenol, 2004;183:1673–89.
37. Wong PC, Li Z, Guo J, Zhang A, Pathophysiology of contrast- induced nephropathy, Int J Cardiol, 2011; July 22 [Epub ahead of print].
38. Battenfeld R, Khater Ae-R, Drommer W, et al., Ioxaglate- induced light and electron microscopic alterations in the renal proximal tubular epithelium of rats, Invest Radiol, 1991;26:35–9.
39. Lautin EM, Freeman NJ, Schoenfeld AH, et al., Radiocontrast- associated renal dysfunction: incidence and risk factors, AJR Am J Roentgenol, 1991;157:49–58.
40. Davidson CJ, Hlatky M, Morris KG, et al., Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial, Ann Intern Med, 1989;110:119–24.
41. Rudnick MR, Goldfarb S, Wexler L, et al., Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study, Kidney Int, 1995;47:254–61.
42. Brezis M, Epstein FH, A closer look at radiocontrast-induced nephropathy, N Engl J Med, 1989;320:179–81.
43. Perazella MA, Radiocontrast-induced nephropathy: an update, Minerva Urol Nefrol, 2009;61:215–33.
44. Rihal CS, Textor SC, Grill DE, et al., Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention, Circulation, 2002;105:2259–64.
45. McCullough PA, Wolyn R, Rocher LL, et al., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality, Am J Med, 1997;103:368–75.
46. Levy EM, Viscoli CM, Horwitz RI, The effect of acute renal failure on mortality. A cohort analysis, JAMA, 1996;275:1489–94.
47. Gruberg L, Mintz GS, Mehran R, et al., The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre- existent chronic renal insufficiency, J Am Coll Cardiol, 2000;36:1542–8.
48. Gupta R, Gurm HS, Bhatt DL, et al., Renal failure after percutaneous coronary intervention is associated with high mortality, Catheter Cardiovasc Interv, 2005;64:442–8.
49. Solomon RJ, Mehran R, Natarajan MK, et al., Contrast-induced nephropathy and long-term adverse events: cause and effect?, Clin J Am Soc Nephrol, 2009;4:1162–9.
50. FDA Drug Safety Communication, New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction, 2010. Available at:
(accessed September 2, 2011).
51. De Campos RO, Heredia V, Ramalho M, et al., Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations, AJR Am J Roentgenol, 2011;196:545–52.
52. Joffe P, Thomsen HS, Meusel M, Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis, Acad Radiol, 1998;5:491–502.
53. Broome DR, Cottrell AC, Kanal E, Response to ‘Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?’, Am J Roentgenol, 2007;189:W234–5.
54. Saitoh T, Hayasaka K, Tanaka Y, et al., Dialyzability of gadodiamide in hemodialysis patients, Radiat Med, 2006;24:445–51.
55. Brar SS, Shen AY, Jorgensen MB, et al., Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial, JAMA, 2008;300:1038–46.
56. Maioli M, Toso A, Leoncini M, et al., Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary
angiography or intervention, J Am Coll Cardiol, 2008;52:599–604.
57. Rudnick MR, Davidson C, Laskey W, et al., Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial, Am Heart J, 2008;156:776–82.
58. Solomon RJ, Natarajan MK, Doucet S, et al., Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease, Circulation, 2007;115:3189–96.
59. Laskey W, Aspelin P, Davidson C, et al., Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures, Am Heart J, 2009;158:822–8 e3.
60. ACT Investigators, Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT), Circulation, 2011;124(11):1250–9.
61. Cruz DN, Perazella MA, Bellomo R, et al., Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review, Am J Kidney Dis, 2006;48:361–71.
62. Marenzi G, Marana I, Lauri G, et al., The prevention of radiocontrast-agent-induced nephropathy by hemofiltration, N Engl J Med, 2003;349:1333–40.
63. Cosgrove D, Ultrasound contrast agents: an overview, Eur J Radiol, 2006;60:324–30.
64. Wilson SR, Greenbaum LD, Goldberg BB, Contrast-enhanced ultrasound: what is the evidence and what are the obstacles?, AJR Am J Roentgenol, 2009;193:55–60.
65. Neuwelt EA, Hamilton BE, Varallyay CG, et al., Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?, Kidney Int, 2009;75:465–74.
66. Maki JH, Wilson GJ, Eubank WB, et al., Steady-state free precession MRA of the renal arteries: breath-hold and navigator-gated techniques vs. CE-MRA, J Magn Reson Imaging, 2007;26:966–73.
67. Taouli B, Koh DM, Diffusion-weighted MR imaging of the liver, Radiology, 2010;254:47–66.
68. Herget-Rosenthal S, Imaging techniques in the management of chronic kidney disease: current developments and future perspectives, Semin Nephrol, 2011;31:283–90.
69. Wang ZJ, Kumar R, Banerjee S, Hsu CY, Blood oxygen level- dependent (BOLD) MRI of diabetic nephropathy: preliminary experience, J Magn Reson Imaging, 2011;33:655–60.
70. Textor SC, Glockner JF, Lerman LO, et al., The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis, J Am Soc Nephrol, 2008;19:780–8.
71. Djamali A, Sadowski EA, Muehrer RJ, et al., BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction, Am J Physiol Renal Physiol, 2007;292:F513–22.
72. Green MA, Hutchins GD, Positron emission tomography (PET) assessment of renal perfusion, Semin Nephrol, 2011;31:291–9.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84